newsfilter
← Latest News
GlobeNewswire·

Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results

Generated $166.8 million in 1Q 2025 revenues, including $149.9 million in U.S. net product salesSYFOVRE® (pegcetacoplan injection) injection demand grew 4% quarter-over-quarter, with U.S. net product revenue of